Drug resistance prominently hampers the effects of sorafenib in hepatocellular carcinoma (HCC). Epigenetics play important roles in drug resistance. However, the contributions of SET And MYND Domain Containing 2 (SMYD2) to sorafenib resistance in HCC remain unknown. This study is aimed at elucidating the role and mechanism of SMYD2 in sorafenib resistance of HCC. Using our well-established sorafenib-resistant hepatocellular carcinoma (HCC) cell lines and xenograft mouse models, we evaluated SMYD2 expression levels. To investigate the biological functions of SMYD2, we conducted a series of functional assays in vitro and in vivo. Transcriptomic profiling via RNA sequencing (RNA-seq) was performed to identify downstream targets of SMYD2. Additionally, chromatin immunoprecipitation (ChIP) assays were employed to elucidate the molecular mechanism. Correlating SMYD2 and target gene expression patterns with clinical outcomes in HCC patients was investigated. SMYD2 expression was significantly elevated in sorafenib-resistant HCC cells compared with parental cells. Knockdown or overexpression of SMYD2 substantially inhibited or enhanced, respectively, HCC stemness and sorafenib resistance. Mechanistically, SMYD2 promoted BMP4 expression via the maintenance of mono-methylation of histone 3 lysine 4 (H3K4me1) and di-methylation of histone 3 lysine 36 (H3K36me2) modification of its promoter. Meanwhile, knockdown or inhibition of BMP4 suppressed the stemness of sorafenib-resistant cells, inhibited the activation of SMAD1/5/8 (R-SMADs), and decreased the expression of inhibitor Of DNA binding 3 (ID3) gene. Moreover, BMP4 addition or ID3 reconstruction can partly reverse the effect caused by repression of SMYD2 or BMP4. HCC patients with positive co-expression of SMYD2/BMP4 or SMYD2/ID3 or SMYD2/BMP4/ID3 exhibited the worst prognosis. Our study reveals that SMYD2 is an important epigenetic mediator that activates BMP4/R-SMADs/ID3 axis, leading to enhanced stemness and sorafenib resistance. Thus, SMYD2 might represent a potential biomarker and future epigenetic therapeutic target for sorafenib resistance of HCC.
Purpose: Emphysematous pyelonephritis (EPN) is a rare, life-threatening necrotizing renal parenchymal infection. It is most commonly reported in patients with poor glycemic control.Patient concerns: We report the case of a 64-year-old woman who presented to the emergency room with fever and weakness over the last few days.Diagnosis: After a series of tests in the diagnostic workup, the patient was diagnosed with emphysematous pyelonephritis and sepsis.Intervention and outcome: She received conservative treatment with meropenem and symptomatic treatment, and the symptoms improved significantly.Lessons: EPN can be reliably diagnosed using non-contrast abdominal CT imaging. The infection is most commonly caused by the Escherichia coli species, and a good curative effect can be achieved with early diagnosis and appropriate and timely treatment.
19 April 2023 in Frontiers in Cellular and Infection Microbiology
Background: Varicella-zoster virus (VZV) is a common and widespread human-restricted pathogen. It is famous for its dermatological manifestations, such as varicella and herpes zoster. Patients with aplastic anemia-paroxysmal nocturnal hemoglobinuria (AA-PNH) syndrome complicated with fatal disseminated varicella zoster virus infection are very rare and in danger.Patient concerns: A 26-year-old man with a history of AA-PNH syndrome was receiving cyclosporine and corticosteroid treatment in the hematology department. During his hospitalization in our hospital, he developed fever, abdominal pain, and lower back pain, and his face, penis, trunk, and limbs developed itchy rash. Subsequently, the patient had to undergo cardiopulmonary resuscitation because of sudden cardiac arrest, and be transferred to ICU for treatment. It was presumed that the cause is unknown severe sepsis. The patient’s condition quickly progressed to multiple organ failure, accompanied by liver, respiratory, and circulatory failure, and signs of disseminated intravascular coagulation. Unfortunately, the patient died after 8 h of active treatment. Finally, we collected all the evidence and concluded that the patient died of AA-PNH syndrome combined with poxzoster virus.Conclusion: AA-PNH syndrome patients treated with steroids and immunosuppressants are prone to various infections, considering that herpes virus infection with chickenpox and rash as the initial manifestations is characterized by rapid progress and often accompanied by serious complications. It is more difficult to distinguish it from AA-PNH syndrome with skin bleeding points. If it is not identified in time, it may delay the treatment opportunity, make the condition worse, and cause serious adverse prognosis. Therefore, clinicians need to pay attention to it.
Anti-cyclic citrulline peptide (anti-CCP) antibodies are among the most critical biomarkers for the diagnosis of rheumatoid arthritis (RA), with citrullinated antigens being pivotal in triggering their production. This study aimed to explore the potential diagnostic value of multiple citrulline similar-motif antigen (MCSM) in RA. A retrospective study was conducted on 135 patients with RA, 112 patients with other joint diseases (non-RA group), and 67 healthy controls from the Hangzhou Red Cross Hospital. The levels of MCSM in the peripheral blood were measured. The diagnostic value of MCSM in RA patients was assessed by receiver operating characteristic (ROC) curve analysis. MCSM in serum were significantly higher in RA patients than in non-RA patients (Signal-to-Cutoff ratio (S/CO): 3.2 vs 0.5, P < 0.0001) and healthy controls (S/CO: 3.2 vs 0.4, P < 0.0001). ROC analysis showed an area under the curve (AUC) of 0.932 for MCSM. Individually, MCSM outperformed anti-CCP and rheumatoid factor (RF), achieving sensitivity of 91.1 % and specificity of 95.5 %. Notably, MCSM detection rates were significantly higher in RA patients with pain duration under one year compared to anti-CCP (89.47 % vs. 52.65 %, P < 0.05). MCSM demonstrate high sensitivity and specificity in diagnosing RA, with significant complementary value to anti-CCP and RF, and can increase the detection rate among RA patients with a disease duration of less than one year.